Premium
Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience
Author(s) -
Hashemi Nikroo,
Viveiros Kathleen,
Redd Walker D.,
Zhou Joyce C.,
McCarty Thomas R.,
Bazarbashi Ahmad N.,
Hathorn Kelly E.,
Wong Danny,
Njie Cheikh,
Shen Lin,
Chan Walter W.
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14583
Subject(s) - medicine , cirrhosis , chronic liver disease , liver disease , diabetes mellitus , mechanical ventilation , retrospective cohort study , covid-19 , obesity , disease , intensive care medicine , infectious disease (medical specialty) , endocrinology
Liver injury has been described with COVID‐19, and early reports suggested 2%‐11% of patients had chronic liver disease (CLD). In this multicentre retrospective study, we evaluated hospitalized adults with laboratory‐confirmed COVID‐19 and the impact of CLD on relevant clinical outcomes. Of 363 patients included, 19% had CLD, including 15.2% with NAFLD. Patients with CLD had longer length of stay. After controlling for age, gender, obesity, cardiac diseases, hypertension, hyperlipidaemia, diabetes and pulmonary disorders, CLD and NAFLD were independently associated with ICU admission ([aOR 1.77, 95% CI 1.03‐3.04] and [aOR 2.30, 95% CI 1.27‐4.17]) and mechanical ventilation ([aOR 2.08, 95% CI 1.20‐3.60] and [aOR 2.15, 95% CI 1.18‐3.91]). Presence of cirrhosis was an independent predictor of mortality (aOR 12.5, 95% CI 2.16‐72.5). Overall, nearly one‐fifth of hospitalized COVID‐19 patients had CLD, which was associated with more critical illness. Future studies are needed to identify interventions to improve clinical outcomes.